Omalizumab Effectiveness in Severe Allergic Asthma with Multiple Allergic Comorbidities: A Post-Hoc Analysis of the STELLAIR Study

BACKGROUND: Immunoglobulin (Ig) E-mediated pathophysiological mechanisms are common in allergic diseases including severe allergic asthma (SAA). The anti-IgE monoclonal antibody omalizumab may be particularly beneficial for patients with SAA and multiple allergic comorbidities (AC) including perenni...

Descripción completa

Detalles Bibliográficos
Autores principales: Just, Jocelyne, Thonnelier, Celine, Bourgoin-Heck, Melisande, Mala, Laurence, Molimard, Mathieu, Humbert, Marc
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2021
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8475967/
https://www.ncbi.nlm.nih.gov/pubmed/34588784
http://dx.doi.org/10.2147/JAA.S310888

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8475967/
https://www.ncbi.nlm.nih.gov/pubmed/34588784
http://dx.doi.org/10.2147/JAA.S310888

Ejemplares similares